VERA News and Press, Vera Therapeutics Inc. From 11/08/23

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Vera Therapeutics Inc. (VERA) is expected to report $-0.5 for Q3 2023

Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients. Additional poster presentations provide further safety analysis of Phase 2b and details of pivotal Phase 3 clinical trial de...

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s m...

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN...

BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s m...

2023-08-17 17:47:04 ET Summary Vera Therapeutics is developing atacicept, a treatment for IgA nephropathy, which showed positive results in Phase 2b trials. The company has strong financials with a cash runway of over two years, but posted an increased net loss in the recent quart...

2023-08-16 14:06:02 ET More on Vera Therapeutics Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target Vera: Repurposed Molecule Program Does Not Impress Novartis deal to buy Chinook rallies Vera Therapeutics Vera Therapeutics slips on $75M...

2023-08-10 12:05:47 ET Vera Therapeutics press release ( NASDAQ: VERA ): Q2 GAAP EPS of -$0.46 beats by $0.23 . Vera reported $181.0 million in cash, cash equivalents, and marketable securities as of June 30, 2023. For further details see: Vera Therapeutics G...

Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60 th ERA Congress Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN Strong balance sheet e...